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Agendas de Investigación sobre Zika
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PRIORIDADES DE COOPERACIÓN 
INTERNACIONAL  DEL SECTOR SALUD 
PARA COMBATIR EL VIRUS DEL ZIKA -
Ministerio de Salud y Protección 
Social - Colombia

Evaluación de la implementación de la 
agenda: identificación de brechas
4
Influencia de Zika sobre casos de 
dengue? 
Cross-protective immunity ZIKV -
Dengue ?
Zika virus infection elicits protective 
immunity?
Plataforma de protocolos sobre ZIKV 
Caracteristicas de estudios incluidos en la Plataforma de 
protocols de investigación de OPS n= 264 
A. Classification of protocols by subtopic, 
N=264*
N (%)  
Clinical management 90 (34.09)
Disease pathogenesis and consequences of infection 37  (14.02)
Epidemiology 79   (29.92)
Ethical aspects 3 (1.14)
Health systems and services response 8 (3.03)
Public health interventions 23  (8.71)
Research and development of products 13 (4.92)
Virus Vectors and Reservoirs 11 (4.17)
A. Type of study, N=76 N (%)  
Basic research 10 (13.16)
Case control 13 (17.11)
Case report 4 (5.26)
Case series 5 (6.58)
Clinical trials 1 (1.32)
Cohort 32 (42.1)
Cross sectional 8 (10.53)
Experimental development 2 (2.64)
Review and cost estimation 1(1.32)
A. Classification of 
protocols by subtopic, 
N=264*
N (%)  
Children 19 (8.92)
Children presenting 
microcephaly 61 (28.64)
GBS 17 (7.98) 
General population 53 (24.88)
Health workers 5 (2.35)
Macaques 2 (0.94) 
Men 5 (2.35)
Military and families 1 (0.47)
Placenta 2 (0.94)
Pregnant women 16 (7.51)
Pregnant women and 
children 31 (14.55) 
Women of reproductive 
age    1 (0.47)
Study 
Population 
General study 
objective 
Follow-
up 
Exposed group Unexposed group Main outcomes 
Children 
presenting 
microcephaly
(n=2) 
Characterize the 
clinical condition and 
describe the 
neurocognitive growth 
and development
2 years HC* ≤ 32 cm born with 37-42 weeks or HC 
≤ percentile 3 (2 SD) on Fenton’s growth 
curve and CT findings consistent with 
congenital CNS infection
Children born with 
normal HC
Visual/ hearing impairment,
Epilepsy
Hospitalizations
Mortality
Pregnant 
women
(n=14)
Estimate the RR for 
congenital 
malformations in  
pregnant women
Birth Pregnant women presenting rash
Asymptomatic cases
Zika+ though PCR
Absence of rash
No clinical symptoms of 
ZIKV infection
Negative laboratory 
result for ZIKV
Miscarriage/stillbirth 
Pregnancy complications
Microcephaly and other 
abnormalities of the central 
nervous system
Pregnant 
women and
their children
(n=19)
Estimate the  RR for 
congenital 
malformations in  
pregnant women
and adverse outcomes 
in pregnancy, 
childbirth and babies
6
weeks-3 
years 
Pregnant woman with rash and fever
Zika+ confirmed by clinical or laboratory 
High risk pregnant woman without 
symptoms, pregnant woman with rash 
and fever, and pregnant women with 
abortionsHIV positive
Pregnant women Microcephaly
Congenital malformations 
Adverse outcomes in children 
Arbovirus+ 
patients 
(n=1) 
Demographic, clinical, 
biological, virologic, 
immunologic genetic 
factors associated with 
arbovirus infections.
12 
weeks 
Suspected of infectious by an arbovirus
Acute febrile/ rash illness consistent with 
arbovirus 
- Adverse outcomes: shock, 
internal bleeding, failure of 
one or several organs or 
systems
Changes in quality of life 
ZIKA+ patients 
(n=1)
To assess the presence 
and duration of 
infectious ZIKV and 
related markers 
4 weeks Positive RT-PCR for ZIKV in a serum or 
urine 
- Incidence rate of ZIKV 
persistence in semen 
Estudios de cohorte N=36
Cohortes sobre Zika en Brazil 
Six standardized protocol designs for the study 
of ZIKV 
1) Cross-sectional seroprevalence study of ZIKV infection in the 
general population 
2) Prospective longitudinal cohort study of ZIKV-infected patients to 
measure the persistence of ZIKV in body fluids 
3) Prospective longitudinal cohort study of women and newborns 
exposed to ZIKV during the course of pregnancy 
4) Prospective longitudinal cohort study of newborns and infants born 
to mothers exposed to ZIKV during pregnancy 
5) Case-control study to assess potential risk factors related to 
microcephaly, including ZIKV infection during pregnancy 
6) Case-control study to assess potential risk factors related to 
Guillain-Barre Syndrome (GBS), including ZIKV infection 
Financiamiento de la Investigación
sobre Zika
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Publicaciones recientes de estudios
primarios sobre zika
11
60%
34%
N=65 estudios primarios / 167 referencias
indexadas recientemente por Pubmed
Publicaciones recientes de estudios
primarios sobre zika
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N=65 estudios primarios / 167 referencias
indexadas recientemente por Pubmed
Publicaciones recientes de 
estudios primarios sobre zika
13
Current literature: 
- Clinical manifestations and 
epidemiology of ZIKV 
- Isolation and Characterization of 
ZIKV
- Development of animal models to 
study ZIKV infection, host immune 
responses against ZIKV, 
- Current state of development of 
vaccines and therapeutics against 
ZIKV
- Diagnostics: serological test; nucleic 
acid amplification tests; imaging 
- Vector control 
Estudios sobre tratamiento:
14
Amjad Ali. Advances in research on Zika virus. Asian Pacific Journal of Tropical Medicine 2017; 10 (4) 321–331;
NIAID utiliza su programa de tamizaje sobre antivirales para evaluar su
efectos sobre Zika. Asimismo se evalúan los medicamentos aprobados por
la FDA. 
“Number of NIH compounds and FDA approved drugs such as have shown potent anti-ZIKV 
activity in vivo as well as in vitro” :
“SaliPhe, CID 91632869, NITD, pyrimidine synthesis inhibitors e.g, brequinar, 6-azauridine and 
finasteride, saliphenylhalamide, gemcitabine, obatoclax, kitasamycinm, lovastatin, 6-azauridine, 
palonosetron, 5-fluorouracil, emricasan, niclosamide, ten cyclin-dependent kinases specifically 
PHA-690509, PHA-690509, sofosbuvir, Type I Interferons, mycophenolic acid (MPA), chloroquine, 
2′-C-methylated nucleosides, azithromycin, T-1105, 2′-C-methylcytidine (2CMC), CX4430 and GS-
5734”
“Accumulating evidence suggest the potent anti-ZIKV activity of number of monoclonal 
antibodies. ZIKV-117 was found to be the most inhibitory antibody that prevented the replication 
of ZIKV and fetal disease in mice. Moreover, another study demonstrate that administration of 
convalescent serum from a subject recovered from ZIKV in pregnant mice resulted in suppression 
of ZIKV likewise, adoptive transfer of purified IgG from vaccinated mice triggered passive 
protection”. 
Ensayos clínicos sobre vacunas:
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Global Observatory on 
Health R&D
“Candidate health products 
(e.g. medicines, vaccines and 
diagnostics) that are currently 
under development are 
reported by disease, product 
name, type, and phase of 
development. 
Inactivated Whole Organism 
(with or without Adjuvant)
DNA vaccines
RNA vaccines
Recombinant Viral Vector
Ensayos clínicos sobre vacunas:
16
Ensayos clínicos sobre vacunas:
17
Monica A. McArthur Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics. Viruses 
2017, 9, 143;
Ensayos clínicos sobre vacunas: ICTRP
18
A Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized (Intra-Group) Clinical Trial to Evaluate Two 
Doses of Three Sequentially Escalating Cohort of Zika Virus Vaccine Inactivated (Adsorbed) (BBV121) in Healthy Adult 
Dengue Sero-Negative and Dengue Sero-Positive Volunteers [05-2017]
Country: India
Participants: Normal healthy male and female volunteers aged between 18 and 65 year
Intervention: Zika vaccine is an inactivated virus vaccine
Outcomes: safety (lab, AE, SAE post vaccination)
Sponsor: private
Not recruiting
A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in 
Healthy Adults and Adolescents [o3-2017]
Countries: Puerto Rico, United States
Participants: part A: 18 to 35; Part B: 15 to 35; Exclusion Criteria: Breast-feeding or planning to become pregnant 
while participating through 12 weeks after the last product administration
Intervention: VRC-ZKADNA090-00-VP
Outcomes: Antibody response 0 to 28 days post product administration; Confirmed cases of Zika Day 0 through Day 
672
Sponsor: VRC, NIAID, NIH and private
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
19
A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito 
Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia [03-2017]
Country: Indonesia
Participants: 3-30 years old; Resided in the study area every night for the 10 days preceding illness onset
Intervention: Wolbachia-infected Aedes aegypti mosquitoes
Outcomes: Zika incidence rate ratio in Wolbachia-treated versus untreated clusters [Time Frame: 24 months 
participant enrolment]
Sponsor: University
Not recruiting
A Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for Red Blood Cells 
in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study) and Treatment Use Open-
Label Extension Study [01-2017]
Countries: Puerto Rico, United States
Participants: 18 Patients who are required or expected to require a transfusion of RBC component(s).
Intervention: INTERCEPT Blood System for Red Blood Cells
Outcomes: Treatment emergent antibodies; AE; adjusted hemoglobin increment averaged over multiple transfusion
Sponsor: Private
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
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A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of 
mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region[01-2017]
Country: United States
Participants: 18 to 49 years of age. - Women of childbearing potential must agree to be heterosexually inactive or 
agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment 
and through 3 months after the final vaccination; Male subjects must use an acceptable method of birth control 
throughout the entire study and agree to refrain from donation of sperm from the time of first vaccination until 3 
months following the last vaccination 
Intervention: mRNA-1325
Outcomes: Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI) 
and adverse events considered related to study drug [Time Frame: Through 13 months of study participation]
Sponsor: Private
Recruiting
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, 
VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults 
[01-2017]
Countries: United States
Participants: 18 to 50 years; excludes female-specific: Breast-feeding or planning to become pregnant while 
participating through 12 weeks after the last study vaccination
Intervention: VRC-ZKADNA090-00-VP
Outcomes: safety and tolerability of v ZIKV DNA vaccine through 44 weeks of study participation; magnitude and the 
frequency of ZIKV-specific antibody response as measured by neutralization assay
Sponsor: NIAID
Not recruiting
Ensayos clínicos sobre vacunas: ICTRP
21
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and 
Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic 
Area [12-2016]
Country: Puerto Rico
Participants: Must be a male or non-pregnant, non-breastfeeding female between the age of 21 and 49 
years, inclusive at the time of screening and enrollment
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Outcomes: study withdrawals and discontinuation of study vaccination due to any reason between dosage groups 
and by pre-vaccination flavivirus immune status [Time Frame: Days 1 to 750]; AE;SAE; Frequency of seroconversion
Sponsor: Private
Recruiting
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, 
VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults 
[01-2017]
Countries: Puerto Rico, United States
Participants: 18 to 50 years; excludes female-specific: Breast-feeding or planning to become pregnant while 
participating through 12 weeks after the last study vaccination
Intervention: VRC-ZKADNA090-00-VP
Outcomes: safety and tolerability of v ZIKV DNA vaccine through 44 weeks of study participation; magnitude and the 
frequency of ZIKV-specific antibody response as measured by neutralization assay
Sponsor: NIAID
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
22
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and 
Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic 
Area [12-2016]
Country: Puerto Rico
Participants: Must be a male or non-pregnant, non-breastfeeding female between the age of 21 and 49 
years, inclusive at the time of screening and enrollment
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Outcomes: study withdrawals and discontinuation of study vaccination due to any reason between dosage groups 
and by pre-vaccination flavivirus immune status [Time Frame: Days 1 to 750]; AE;SAE; Frequency of seroconversion
Sponsor: Private
Recruiting
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a 
New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers [12-2016]
Countries: Austria
Participants: healthy volunteers aged 18 to 55; subjects of child bearing potential must perform reliable method of 
contraception
Intervention: MV-ZIKA
Outcomes: Immunogenicity: Functional anti-Zika antibodies as measured by PRNT [Time Frame: 56 days]
Sponsor: Private
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
23
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated 
Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
Country: Puerto Rico
Participants: Must be a male or non-pregnant, non-breastfeeding female between the ages of 18 and
49 years, inclusive, at the time of screening and enrollment
Intervention: IXIARO; YF Vax 17D Strain; Zika Virus Purified Inactivated Vaccine (ZPIV)
Outcomes: AE; SAE; Anti- ZIKV NAbs GMTs; Anti- ZIKV NAbs seroconversion
Sponsor: Private
Recruiting
Phase 1, Double-blinded, Placebo-Controlled Dose De-escalation Study of the Safety and Immunogenicity of Alum 
Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve 
Adult Subjects [10 - 2016]
Countries: USA
Participants: Must be a male or non-pregnant, non-breastfeeding female between the age of 18 and 49
years, inclusive at the time of screening and enrollment; Women of childbearing potential* must have a negative 
serum pregnancy test at screening and a negative urine pregnancy test immediately prior to each vaccination Note: 
All female subjects are considered of childbearing potential unless postmenopausal or surgically sterilized and >/=3 
months have passed since sterilization procedure. Postmenopausal is defined as amenorrhea for >/=12 months
without an alternative medical cause. Permanent female sterilization procedures include tubal ligation, bilateral 
salpingectomy, hysterectomy, bilateral oophorectomy, or successful Essure placement. Women of childbearing 
potential must use an acceptable method of contraception from one month (30 days) prior to the first vaccination 
until at least 60 days after the last vaccination; Acceptable methods of contraception include the following: …
Intervention: Biological: Zika Virus Purified Inactivated Vaccine (ZPIV)
Outcomes: local or systemic reactogenicityAE;SAE; GMT; seroconversion
Sponsor: (NIAID)
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
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A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 
an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy 
Adults [12-2016]
Country: Puerto Rico
Participants: Age 18-50 years old.
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Outcomes: study withdrawals and discontinuation of study vaccination due to any reason between dosage groups 
and by pre-vaccination flavivirus immune status [Time Frame: Days 1 to 750]; AE;SAE; Frequency of seroconversion
Sponsor: Private
Recruiting
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a 
New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers [12-2016]
Countries: Austria
Participants: healthy volunteers aged 18 to 55; subjects of child bearing potential must perform reliable method of 
contraception; 7. All female participants must be willing to undergo serum or urine beta human chorionic 
gonadotropin pregnancy tests at time points indicated in the Schedule of Procedures and must test negative prior to 
vaccination. All sexually active males (unless anatomically sterile) must be willing to use an effective method of 
contraception (such as consistent condom use) from the day of first vaccination until Week 12. If a woman of child-
bearing potential, committed to use an effective method of contraception when sexually active with men until Week 
12, including: Condoms (male or female) with or without spermicide; Diaphragm or cervical cap with spermicide; 
Intrauterine device; Hormonal contraception; Successful vasectomy in the male partner (considered successful if a 
woman reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more 
than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy).
Outcomes: Immunogenicity: AE; SAE [Time Frame: 56 days]; IFN-? ELISPOT responses to prM, Env, Cap, and NS1 
peptides; Elisa titers, neutralization etc
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Walter Reed Army Institute of Research 
Recruiting
Ensayos clínicos sobre vacunas: ICTRP
25
Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, 
Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults [08-2016]
Country: Puerto Rico
Participants: 18-65 years.
Intervention: GLS-5700
Outcomes: AE;SAE; Binding antibody titers to Zika envelope; Neutralizing antibody response against Zika virus
Sponsor: Private
Recruiting
VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-
ZKADNA085-00-VP, in Healthy Adults [07-2016]
Countries: USA
Participants: 18 to 35 years old
Intervention: ZIKV DNA vaccine VRC-ZKADNA085-00-VP
Outcomes: safety and tolerability through 44 weeks of study participation]; magnitude and frequency of ZIKV-specific antibody 
response as measured by neutralization assay
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID 
Followed by EP in Dengue Virus-Naïve Adults 
Country: Canada; United States
Participants: Age 18-65 years; Women of child-bearing potential agree to use medically effective contraception(oral contraception, 
barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have 
a partner who is medically unable to induce pregnancy. Sexually active men who are considered sexually fertile must agree to use 
either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last 
injection, or have a partner who is permanently sterile or is medically unable to become pregnant
Intervention: GLS-5700
Outcomes: SEA;AE; Binding antibody titers to Zika envelope; Neutralizing antibody response against Zika virus 
Sponsor: Private
